Omeros (OMER) to Release Earnings on Tuesday

Omeros (NASDAQ:OMER) is anticipated to release its Q4 2025 results after the market closes on Tuesday, March 3rd. Analysts expect Omeros to post earnings of ($0.57) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

Omeros Price Performance

NASDAQ:OMER opened at $12.05 on Monday. The company has a 50-day moving average of $12.63 and a 200 day moving average of $8.71. Omeros has a 1-year low of $2.95 and a 1-year high of $17.65. The firm has a market cap of $854.35 million, a PE ratio of -5.97 and a beta of 2.45.

Insider Activity

In other news, CAO David J. Borges sold 30,000 shares of the company’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total value of $369,300.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 12.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in OMER. Vanguard Group Inc. lifted its position in shares of Omeros by 1.9% during the third quarter. Vanguard Group Inc. now owns 3,346,958 shares of the biopharmaceutical company’s stock worth $13,723,000 after purchasing an additional 63,381 shares in the last quarter. Geode Capital Management LLC boosted its position in Omeros by 6.3% in the 4th quarter. Geode Capital Management LLC now owns 1,631,350 shares of the biopharmaceutical company’s stock valued at $28,026,000 after buying an additional 95,979 shares during the period. State Street Corp grew its stake in shares of Omeros by 26.9% in the fourth quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock worth $27,025,000 after acquiring an additional 333,798 shares in the last quarter. Two Sigma Investments LP increased its position in shares of Omeros by 39.3% during the third quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock worth $3,827,000 after acquiring an additional 263,095 shares during the period. Finally, Marshall Wace LLP increased its position in shares of Omeros by 15.1% during the second quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company’s stock worth $2,224,000 after acquiring an additional 97,224 shares during the period. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Omeros in a research note on Thursday, January 22nd. Wall Street Zen downgraded shares of Omeros from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. D. Boral Capital restated a “buy” rating and set a $36.00 price objective on shares of Omeros in a research note on Tuesday, January 27th. Finally, HC Wainwright boosted their price objective on Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $40.33.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.